Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02474901 · ClinicalTrials.gov registry record · Phase 2
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT02474901 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 101 participants.
The verdict
NCT02474901, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are receiving the quadrivalent live-attenuated influenza vaccine (QLAIV).
Interventions
- BIOLOGICAL Quadrivalent Live Attenuated Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02474901
The ClinicalTrials.gov registry entry for NCT02474901 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quadrivalent Live Attenuated Influenza Vaccine is the first listed.
NCT02474901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02474901 about?
NCT02474901 is a clinical study titled "Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults". The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are receiving the quadrivalent live-attenuated influenza vaccine (QLAIV).
What is the current status of trial NCT02474901?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2013-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02474901?
The interventions under investigation include: Quadrivalent Live Attenuated Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02474901?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.